InvestSMART

BlinkLab Limited (ASX:BB1)

ALERT: Price-sensitive ASX Announcement for BB1
Current share price for BB1 : $0.640 0.1 (18.52%)+
Announcement
Release
28 Aug 2025 6:23PM
Price at Release
$0.540
Full Release
download
Summary
The 2023 Annual Report & Appendix 4E of BlinkLab Limited provides an overview of the company’s activities, achievements, and financial performance for its newly adopted calendar year reporting period. The report highlights advancements in the development and validation of the BlinkLab mobile neurobehavioral assessment platform, ongoing clinical studies, and strategic collaborations. Despite limited revenue, the company continued to invest in research and development, raising new funds to sustain operations, and made progress in building its intellectual property and regulatory standing. The Board and management remain focused on commercialising their innovative technology and addressing industry risks, as detailed in the comprehensive financial and governance disclosures presented in the report.
Key Points
  • BlinkLab Limited has released its Annual Report & Appendix 4E for the year ended 31 December 2023.
  • The company changed its financial year end from 30 June to 31 December as approved by shareholders at the 2023 AGM.
  • The report details continued product development, pilot studies, and key milestones in advancing the commercialisation of their mobile-based neurobehavioral assessment platform.
  • Significant achievements include the launch of the updated BlinkLab App, progression of clinical validation studies in Europe and the US, and partnerships with academic and commercial entities.
  • Revenue for the period was modest, primarily from research and development tax incentives, with operating losses reflecting ongoing investment in product development and clinical trials.
  • The company raised additional capital via a share placement and convertible note to support continued operations and growth.
  • Emphasis was placed on expanding the intellectual property portfolio, securing patents, and enhancing regulatory compliance.
  • Risks identified include competition, clinical trial outcomes, regulatory changes, and reliance on key personnel.
  • The Board remains confident in the growth prospects and future commercialisation of BlinkLab’s technology.
  • Governance, financial statements, auditor's report, and remuneration details are included, meeting compliance requirements for ASX-listed entities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.